{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:13Z","timestamp":1789578313189,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.02.020","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:38:38Z","timestamp":1772253518000},"page":"814-821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Long Noncoding RNA\u2013based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity"],"prefix":"10.1016","volume":"9","author":[{"given":"Tran Anh","family":"Thu Phung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9836-1434","authenticated-orcid":false,"given":"Ewan A.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.02.020_b0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bju.14995","article-title":"Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)","volume":"125","author":"Matulay","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.02.020_b0015","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","article-title":"Cancer-specific survival of patients with non-muscle-invasive bladder cancer: a population-based analysis","volume":"30","author":"Slusarczyk","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.euo.2026.02.020_b0020","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466\u201375; discussion 475\u20137.","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"10.1016\/j.euo.2026.02.020_b0025","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.020_b0030","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","article-title":"Superficial bladder cancer: progression and recurrence","volume":"130","author":"Heney","year":"1983","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0035","doi-asserted-by":"crossref","unstructured":"Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000;163:60\u20131; discussion 61\u20132.","DOI":"10.1016\/S0022-5347(05)67972-4"},{"key":"10.1016\/j.euo.2026.02.020_b0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0094-0143(03)00060-0","article-title":"Evaluation and follow-up strategies for superficial bladder cancer","volume":"30","author":"Donat","year":"2003","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euo.2026.02.020_b0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2490-14-5","article-title":"Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression","volume":"14","author":"Kobayashi","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0050","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0055","unstructured":"National Comprehensive Cancer Network. Bladder cancer (version 5.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"10.1016\/j.euo.2026.02.020_b0060","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0070","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MOU.0b013e3281c55f2b","article-title":"Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer","volume":"17","author":"Hendricksen","year":"2007","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4103\/0970-1591.166446","article-title":"Intravesical chemotherapy in non-muscle-invasive bladder cancer","volume":"31","author":"Porten","year":"2015","journal-title":"Indian J Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.euf.2023.06.012","article-title":"Long-term recurrence rates of low-risk non-muscle-invasive bladder cancer-how long is cystoscopic surveillance necessary?","volume":"10","author":"Ma","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.02.020_b0085","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/JU.0000000000004305","article-title":"Long-term recurrence risk, metastatic potential, and length of cystoscopic surveillance of low-grade non-muscle-invasive bladder cancer","volume":"213","author":"Villegas","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4103\/0974-7796.184891","article-title":"Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical bacillus Calmette-Guerin: a single center experience and analysis of prognostic factors","volume":"8","author":"Bazarbashi","year":"2016","journal-title":"Urol Ann"},{"key":"10.1016\/j.euo.2026.02.020_b0095","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0100","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jmoldx.2024.08.005","article-title":"A versatile and upgraded version of the LundTax classification algorithm applied to independent cohorts","volume":"26","author":"Cotillas","year":"2024","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.euo.2026.02.020_b0105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urolonc.2019.11.004","article-title":"Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy","volume":"38","author":"Grivas","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.020_b0110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2019.04.036","article-title":"Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors","volume":"76","author":"Lotan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0120","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JU.0000000000002261","article-title":"Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy","volume":"207","author":"Lotan","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0125","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0130","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.euo.2026.02.020_b0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical bacillus Calmette-Guerin","volume":"15","author":"de Jong","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.euo.2026.02.020_b0140","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","article-title":"Identification of differential tumor subtypes of T1 bladder cancer","volume":"78","author":"Robertson","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.020_b0145","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.euo.2025.05.013","article-title":"Long noncoding RNAs identify a subgroup of patients with low-grade non-muscle-invasive bladder cancer with less favorable outcomes","volume":"8","author":"de Jong","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.020_b0150","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.02.020_b0155","article-title":"Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.euo.2026.02.020_b0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.euo.2026.02.020_b0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-019-0669-z","article-title":"Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis","volume":"11","author":"de Jong","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.euo.2026.02.020_b0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41467-017-00147-w","article-title":"Evasion of immunosurveillance by genomic alterations of PPARgamma\/RXRalpha in bladder cancer","volume":"8","author":"Korpal","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.02.020_b0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13193-018-0728-8","article-title":"Low-grade, multiple, Ta non-muscle-invasive bladder tumors: tumor recurrence and worsening progression","volume":"9","author":"Nerli","year":"2018","journal-title":"Indian J Surg Oncol"},{"key":"10.1016\/j.euo.2026.02.020_b0180","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/bju.16572","article-title":"A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy","volume":"135","author":"de Jong","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.02.020_b0185","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.euo.2026.02.020_b0190","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccell.2014.09.001","article-title":"Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors","volume":"26","author":"Shin","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2026.02.020_b0195","first-page":"4945","article-title":"Prognostic significance of mucin expression in urothelial bladder cancer","volume":"7","author":"Stojnev","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.euo.2026.02.020_b0200","doi-asserted-by":"crossref","first-page":"443.e1","DOI":"10.1016\/j.urolonc.2025.03.009","article-title":"Differential response of low- and high-grade intermediate-risk non-muscle-invasive bladder cancer to bacillus Calmette-Guerin and gemcitabine-docetaxel therapy","volume":"43","author":"Eraky","year":"2025","journal-title":"Urol Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112600057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112600057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:46:25Z","timestamp":1789577185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112600057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S258893112600057X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.020","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Long Noncoding RNA\u2013based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}